Receive The Newest Study Notifications

ICON Launches New Patient Engagement Platform to Support Improved Patient Experience and Enrollment in Clinical Trials

by Lance Smith | May 9, 2019 | Study Scavenger Clinical Trial Recruitment Platform

Increasing visibility of potential study participants to sites and sponsors -ICON plc, (NASDAQ: ICLR) a global provider of drug and device development and commercialisation services to the pharmaceutical, biotechnology and medical device industries, today announced...

Promethera Biosciences Announces First-Dosing in Phase 2a Clinical Study Evaluating World’s First Liver Stem Cell Therapy in Late-Stage NASH Patients

by Lance Smith | May 9, 2019 | Study Scavenger Clinical Trial Recruitment Platform

Promethera Biosciences SA, a global innovator in cell-based medicines and liver diseases, today announced the dosing of a first patient in a Phase 2a clinical study for the company’s HepaStem development program in patients with late stage non-alcoholic...

Provention Bio Announces Top-Line Results from its Phase 1b PULSE Clinical Trial of PRV-300 in Patients with Moderate-to-Severe Ulcerative Colitis

by Lance Smith | May 9, 2019 | Study Scavenger Clinical Trial Recruitment Platform

Provention Bio, Inc. (Nasdaq: PRVB), a clinical stage biopharmaceutical company dedicated to intercepting and preventing immune-mediated diseases, today announced preliminary top-line results from its Phase 1b PULSE study which evaluated PRV-300, an anti-TLR3...

MaxCyte Progresses Phase I Clinical Trial of Lead mRNA-based Cell Therapy from its CARMA™ Platform

by Lance Smith | May 9, 2019 | Study Scavenger Clinical Trial Recruitment Platform

– No dose-limiting toxicities or safety concerns observed in first cohort of treated patients – Feasibility of streamlined, faster CAR therapy manufacturing process confirmed – Dosing initiated in second cohort of patients MaxCyte, the global...

Shattuck Labs, Inc. Announces Initiation of Phase 1 Clinical Trial of SL-279252 (PD1/OX40L)

by Lance Smith | May 7, 2019 | Study Scavenger Clinical Trial Recruitment Platform

SL-279252 is the first Agonist Redirected Checkpoint molecule to enter clinical development from the Shattuck pipeline. Shattuck Labs, Inc. (“Shattuck”), a biopharmaceutical company, announced today that patients are being treated in its Phase 1 dose escalation and...

Can-Fite Announces Preparation for End-of-Phase II Meeting with FDA to Initiate the Phase III Liver Cancer Study for Namodenoson

by Lance Smith | May 7, 2019 | Study Scavenger Clinical Trial Recruitment Platform

Fast Track and Orphan Drug Status; No treatment currently exists for advanced liver cancer patients in whom the current standard of care does not work Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE:CFBI), a biotechnology company with a pipeline of proprietary...